Earnings call transcripts

Management framed the quarter as evidence that AI-driven resilience demand can support simultaneous growth, platform expansion, and margin scaling.

Management framed the AMD agreement as validation of its build-ahead strategy, shifting emphasis from contract announcements to delivery and repeatable execution.

Management framed the quarter around unusually tight refining markets, planned portfolio separation, and deploying excess cash selectively rather than accumulating it.

Management framed the quarter as evidence of accelerating commercial adoption, while positioning KPL 387 as a potential second growth driver.

Management framed the quarter as broad-based momentum built through consumer-focused execution, while tempering the headline pace with easier comparisons and temporary event benefits.

Management framed the post-mobility company as a higher-margin benchmark platform, with AI distribution and portfolio simplification funding growth.

Management framed Alkermes as increasingly differentiated in orexin biology while using commercial cash flow to fund multiple new indications.

Management framed accelerating AI and networking demand, improving supply planning, and ramp execution as supporting a higher 2026 outlook and faster 2027 growth.

Management framed the call around accelerating load growth, a larger investment plan, and confidence in execution without near-term equity needs.

Management framed the first public-company call around accelerating demand, execution against a record backlog, and confidence in profitable growth.

Management framed Q2 as evidence its turnaround is gaining traction, while stressing that broader growth benefits will take years to emerge.

Management framed the quarter as broad-based demand improvement, raising outlook while emphasizing that equipment recovery remains chiefly a 2027 opportunity.